DIAGENS-B's stock price surged 22.29% during the morning trading session on Tuesday, marking a significant upward movement for the healthcare technology company.

The sharp increase followed the company's announcement that its self-developed AI AutoVision® chromosome karyotype assisted diagnosis software has officially received a Class III Medical Device Registration Certificate from China's National Medical Products Administration. This certification covers chromosome analysis for prenatal diagnosis and assisted reproduction applications.

According to the company, this represents the world's first Class III medical device registration certificate for chromosome karyotype analysis with L3-level anomaly recognition capabilities, and it's also the first such certificate obtained based on large model technology. The board stated that this regulatory approval reflects official recognition of the safety, effectiveness, and clinical value of their iMedImage® medical imaging large model technology.